Pulmonary Alveolar Proteinosis Refractory to Plasmapheresis and Rituximab despite GM-CSF Antibody Reduction
Case Reports in Immunology · 30.01.2022 · 2022 · 1-4
DOI: 10.1155/2022/2104270 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Immunology, erschienen am 30.01.2022. Verfasst von Aysenur Keske und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Wisconsin Hospital, 600 Highland Ave, Madison, WI 53792, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We share our experience of a patient with pulmonary alveolar proteinosis who was refractory to plasmapheresis and rituximab despite a significant reduction in the offending antibody. He presented with shortness of breath, fevers, chills, and sweats for 4 months. He was diagnosed with autoimmune PAP based on typical radiology findings, bronchoalveolar fluid analysis, and elevated anti-GM-CSF levels. Given his limited improvement with whole lung lavage and inhaled GM-CSF therapy, he underwent two series of plasmapheresis. Series one was 5 procedures in 6 days, and series two was 5 procedures in 9 days followed by rituximab. These did not appear to provide any lasting clinical benefit in the year after plasmapheresis despite a marked decrease in serum anti-GM-CSF levels. However, about a year after plasmapheresis, he went into remission and has not required any treatment.
Autor:innen und Institutionen
- Department of Pathology, University of Wisconsin Hospital, 600 Highland Ave, Madison, WI 53792, USA.
ORCID-Profile: William N Rose
Zitieren
APA
Keske, A., Destrampe, E. M., Barksdale, B., & Rose, W. N. (2022). Pulmonary Alveolar Proteinosis Refractory to Plasmapheresis and Rituximab despite GM-CSF Antibody Reduction. Case Reports in Immunology, 2022, 1-4. https://doi.org/10.1155/2022/2104270
Vancouver
Keske A, Destrampe EM, Barksdale B, Rose WN. Pulmonary Alveolar Proteinosis Refractory to Plasmapheresis and Rituximab despite GM-CSF Antibody Reduction. Case Reports in Immunology. 2022;2022:1-4. doi:10.1155/2022/2104270
BibTeX
@article{Keske2022,
author = {Keske, Aysenur and Destrampe, Eric M and Barksdale, Byron and Rose, William N},
title = {Pulmonary Alveolar Proteinosis Refractory to Plasmapheresis and Rituximab despite GM-CSF Antibody Reduction},
journal = {Case Reports in Immunology},
year = {2022},
volume = {2022},
pages = {1--4},
doi = {10.1155/2022/2104270}
}
EUVIMED